



Targeted Therapies in Cardiovascular and Kidney Diseases

Guest Editors:

Dr. Assaad A. Eid

Prof. Dr. Koyo Nishida

Dr. Gene L. Bidwell, III

Dr. Rachel Njeim

Dr. Antony F. Haddad

Rashad Nawfal

Deadline for manuscript
submissions:
closed (20 August 2023)

Message from the Guest Editors

Dear Colleagues,

Despite the various scientific and medical efforts invested into understanding the multitude of known kidney diseases, direct therapies to treat some of the most prevalent kidney disorders are yet to be identified. Furthermore, even though targeted therapies such as tyrosine kinase inhibitors, VEGF inhibitors, mTOR blockers and others are currently being used to tackle the progression of advanced kidney cancer, according to the American Cancer Society, these targeted therapies “Sometimes work when standard chemo drugs don’t”, but “it doesn’t seem that any of these drugs can actually cure kidney cancer”. Therefore, scientists have started focusing their research on the successful use of targeted therapies for kidney diseases, with multiple studies showing promise.

In this Special Issue of *Pharmaceutics* on “Targeted Therapies in Kidney Diseases”, attempts to describe, discover and repurpose drug treatments for nephropathy, nephrotic syndrome, nephritic syndrome, CKD, AKI, polycystic kidney disease, Alport syndrome and kidney cancer will be highlighted.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma